US92764N1028 - Common Stock
VIR BIOTECHNOLOGY INC
NASDAQ:VIR (11/4/2024, 8:00:02 PM)
After market: 9.0512 -0.32 (-3.4%)9.37
+0.11 (+1.19%)
Vir Biotechnology, Inc. operates as a clinical-stage immunology company that focuses on combining immunologic insights with cutting-edge technologies to treat and prevent serious infectious diseases. The company is headquartered in San Francisco, California and currently employs 587 full-time employees. The company went IPO on 2019-10-11. The firm's clinical development pipeline consists of product candidates targeting hepatitis delta virus (HDV), hepatitis B virus (HBV), and human immunodeficiency virus (HIV). The company also has several preclinical candidates in its pipeline including those targeting influenza A and B, COVID-19, respiratory syncytial virus and human metapneumovirus (RSV and MPV), and human papillomavirus (HPV). The firm's pipeline includes VIR-1949, VIR-7229, VIR-2981, VIR-8190, and HIV Cure. The company also engaged in developing tobevibart, a monoclonal antibody also known as VIR-3434, and Elebsiran, an siRNA also known as VIR-2218, for the treatment and suppression of chronic HDV. Its Elebsiran is an investigational HBV-targeted siRNA that reduces HBsAg, a protein which is required for the HDV viral life cycle.
VIR BIOTECHNOLOGY INC
1800 Owens Street, Suite 900
San Francisco CALIFORNIA 94158
P: 14159064324
CEO: George Scangos
Employees: 587
Website: https://www.vir.bio/
Intrigued by the market activity in the middle of the day on Friday? Uncover the key winners and losers of today's session in our insightful analysis.
Here you can normally see the latest stock twits on VIR, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.
Example Twits: